ArticleCureus2025
Fatal Neutropenia Sepsis Following Acute Methotrexate Toxicity.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Methotrexate (MTX) is widely used to manage autoimmune diseases such as rheumatoid arthritis, psoriasis, and eczema due to its anti-inflammatory and immunosuppressive properties. We present the case of a 69-year-old male individual with stage 3b chronic kidney disease (CKD) and diabetes mellitus, who developed acute MTX toxicity following a dosing error. The patient, prescribed MTX 7.5 mg weekly for chronic lower leg eczema, mistakenly took 5 mg every eight hours for four days. He presented with erythematous rashes, oral mucosal ulcerations, and pancytopenia, later diagnosed as neutropenic sepsis. Management included discontinuation of MTX, intravenous folinic acid, granulocyte-macrophage colony-stimulating factor (GM-CSF), and broad-spectrum antibiotics. By day 7, his blood counts and symptoms improved, and he was discharged on day 12. This case underscores the importance of patient education on proper MTX dosing to prevent life-threatening complications, particularly in high-risk populations such as the elderly and those with CKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.